Medication info

Linagliptin/Metformin Tablets 2.5/1000 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Biconvex bright pink oval film-coated tablets
Packaging
60 tablets (10 tablets/PTP x 6)
Approval status
Expired

MFDS item code 201905403 · Approved 2019.07.30

This product's status changed to Expired on 2024.07.30. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment experience who cannot achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. Inadequate glycemic control with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). Switching from combination therapy with linagliptin and metformin: Patients switching to this medicine from combination therapy with linagliptin and metformin should start with their previous doses of linagliptin and metformin. Inadequate glycemic control with concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. Inadequate glycemic control with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis: Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication aids in blood sugar control for patients with Type 2 diabetes when Linagliptin and Metformin are used together. It is effective in improving blood sugar levels when combined with diet and exercise therapy. Regular intake can greatly assist in blood sugar management.

How to take

Adult dose

The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment experience who cannot achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. Inadequate glycemic control with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). Switching from combination therapy with linagliptin and metformin: Patients switching to this medicine from combination therapy with linagliptin and metformin should start with their previous doses of linagliptin and metformin. Inadequate glycemic control with concomitant metformin and sulfonylurea therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. Inadequate glycemic control with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis: Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication helps in blood sugar control. However, it may rarely cause a serious side effect known as lactic acidosis, so caution is warranted. You should not take this medication if you have an allergy to its ingredients or have certain conditions such as Type 1 diabetes, lactic acidosis, diabetic ketoacidosis, or diabetic pre-coma. Patients with severely impaired kidney function or significant liver dysfunction, dehydrated patients, or those with severe infections should also avoid this medication. Additionally, it is safest for patients with acute alcohol intoxication or alcoholism, malnutrition, heart failure, or pregnant or breastfeeding women to refrain from taking this medication. When taking this medicine, symptoms of hypoglycemia may occur, so it is essential to monitor blood sugar changes closely, especially when taking it together with sulfonylureas or insulin. Due to the risk of lactic acidosis, if kidney function deteriorates suddenly or if there are respiratory diseases or septicemia, stop taking the medication immediately and consult your physician. Regular kidney function tests should be conducted to ensure the safe use of this medication, and dosing should be stopped if kidney function declines. Patients with weakened heart function should regularly monitor their cardiac and renal conditions while using this medication. When undergoing radiological examinations that involve iodinated contrast agents, the use of this medication should be temporarily suspended before and after the administration of the contrast agent and kidney function should be reassessed. Patients preparing for surgery should stop taking this medication 48 hours before the surgery and resume after kidney function has recovered post-operation. If acute pancreatitis or blistering skin diseases are suspected, stop the medication and consult a physician immediately. Gastrointestinal disturbances, hypoglycemia, vitamin B12 deficiency, myalgia, skin rashes, and other side effects may occur during use, so it is important to inform medical personnel of any unusual symptoms. This medication may interact with other drugs, so be sure to inform your doctor or pharmacist about any other medications you are taking. Pregnant or breastfeeding women are advised to avoid this medication, and if you plan to become pregnant, consult with your doctor before determining a treatment approach. Elderly patients have a higher likelihood of reduced kidney function, so it is safe to start at the minimum dose along with regular kidney function tests. In the case of overdose, the medication may not be fully absorbed in the gastrointestinal tract, and there is a risk of lactic acidosis, so hospital treatment is required immediately. This medication should be stored out of reach of children and protected from moisture.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 147 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • formation of mouth ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • pemphigoid-like reaction
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer-type dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage kidney disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • chest discomfort
  • weakness
  • pain
  • nosebleed
  • oropharyngeal pain
  • speech disorder
  • allergic rhinitis
  • exertional dyspnea
  • wet cough
  • runny nose
  • pulmonary mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • male pattern hair loss
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • delirium
  • nocturia
  • pruritus
  • hypertension
  • erectile dysfunction
  • goiter
  • vascular disorders
  • hypotension
  • flushing
  • hearing loss
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • benign prostatic hyperplasia
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • stomatitis
  • mediastinitis
  • rhinitis
  • gingivitis
  • influenza
  • folliculitis
  • soft tissue infection
  • upper respiratory infection
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • increased serum creatinine
  • facial swelling
  • hyperthermia
  • back pain
  • dizziness
  • diabetic neuropathy
  • headache
  • subdural effusion
  • corneal abrasion
  • fall
  • upper limb fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container when not in use. Moreover, it is best kept at room temperature, between 1 to 30 degrees Celsius, avoiding extremes of heat or cold.

Appearance and packaging

Appearance

Biconvex bright pink oval film-coated tablets

Package unit

60 tablets (10 tablets/PTP x 6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.